Loading…
Diversified pharma spanning vaccines, oncology and internal medicine, best known for its COVID-19 vaccine/Paxlovid.
Diversified pharma spanning vaccines, oncology and internal medicine, best known for its COVID-19 vaccine/Paxlovid.
Sells patented medicines and vaccines through health systems, pharmacies and governments; Covid products made revenue swell and then shrink. It bought Seagen in 2023 to build its cancer-drug range, and several major products face patent expiry.
Moat: narrow (scale, IP / patents, distribution). Broad commercial and manufacturing scale but facing patent cliffs across several major products.
Headquarters: New York, New York, United States · Founded: 1849 · Employees: 75,000
Size Pfizer (PFE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $168B, the 75th largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.39 on 6 Nov 2026.
Performance Over six months the shares gained 14.4%, against +18.0% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 1.3% over the last twelve months (peer median +6.1%); the operating margin is 25.9% (peer median 27.3%).
Valuation It trades at 10.4× forward earnings against a peer median of 18.3× (3rd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.4 points above its cost of capital (6.1% WACC).
Credit Pfizer has 38 bonds outstanding ($58.0B), rated A by the agencies and trading like A+ at a weighted spread of 66 bp.
Short interest Short interest is 2.4% of the free float (15 Oct 2026).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $63.6B | $62.6B | $63.6B | $59.6B | $100B |
| Revenue growth | — | -2% | +7% | -41% | — |
| Gross profit | $41.4B | $41.0B | $41.8B | $30.3B | $62.1B |
| EBITDA | $23.0B | $23.7B | $23.5B | $11.6B | $42.6B |
| Net income | $4.03B | $7.77B | $8.02B | $2.13B | $31.4B |
| Free cash flow | $11.8B | $9.08B | $9.84B | $4.79B | $30.0B |
| Capital expenditure | $2.39B | $2.63B | $2.91B | $3.91B | $3.24B |
| Total debt | $62.7B | $67.4B | $67.0B | $75.0B | $39.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pfizer PFE | $168B | +14% | +1% | 26% | 10.4× | -4.3% |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Moderna MRNA | $101B | +43% | -28% | -149% | n/a | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 9.7× | -12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PFE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.6% | +10.2% | 5th lowest of 21 |
| 6-month return | +14.4% | +18.0% | 9th lowest of 21 |
| Distance from 52-week high | -6.5% | -8.3% | 10th highest of 21 |
| Revenue growth (TTM) | +1.3% | +6.1% | 5th lowest of 21 |
| Operating margin | 25.9% | 27.3% | 10th lowest of 21 |
| Forward P/E | 10.4× | 18.3× | 3rd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -4.3% | 3.3% | 3rd least demanding of 21 |
| Growth delivered (Del g) | +8.5% | +6.7% | 10th highest of 21 |
| Hurdle (Req g minus delivered) | -12.8 pp | -4.7 pp | 6th least demanding of 21 |
| ROIC minus cost of capital | +3.4 pp | +11.2 pp | 4th lowest of 21 |
| EV / EBITDA | 9.4× | 15.1× | 6th cheapest of 18 |
| Net debt / EBITDA | 2.1× | 1.2× | 4th most indebted of 18 |
| Bond spread | 66 bp | 66 bp | 8th tightest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pfizer PFE | United States | $168B | +14% | +1% | 26% | 10.4× | -4.3% | +8.5% |
| Novo Nordisk A/S NOVO-B.CO | Denmark | $190B | -7% | +6% | 48% | 11.9× | 0.1% | +19.5% |
| Vertex Pharmaceuticals VRTX | United States | $139B | +27% | +11% | 35% | 29.0× | 6.1% | +14.2% |
| Bristol Myers Squibb BMY | United States | $127B | +12% | +4% | 33% | 9.7× | -12.9% | +2.5% |
| Sanofi SAN.PA | France | $113B | +14% | +15% | 27% | 9.6× | -5.4% | +3.9% |
| GSK GSK.L | United Kingdom | $102B | 0% | +4% | 25% | 10.6× | -0.1% | -0.9% |
| AstraZeneca AZN.L | United Kingdom | $291B | +1% | +5% | 23% | 18.3× | 14.5% | +15.7% |
| Novartis NOVN.SW | Switzerland | $298B | +15% | -4% | 30% | 18.4× | 1.7% | -0.2% |
| Regeneron Pharmaceuticals REGN | United States | $93.5B | +27% | +19% | 30% | 11.3× | -2.2% | +11.0% |
| Merck & MRK | United States | $362B | +33% | +5% | 18% | 17.4× | 4.1% | +9.3% |
| Roche RO.SW | Switzerland | $385B | +22% | -1% | 31% | 19.6× | 0.9% | +1.1% |
| Merck KGaA MRK.DE | Germany | $72.5B | +23% | 0% | 20% | 17.5× | 7.7% | +3.8% |
| Chugai Pharmaceutical 4519.T | Japan | $71.0B | -15% | +17% | 50% | 22.1× | 3.6% | +9.8% |
| WuXi AppTec 603259.SS | China | $67.0B | +34% | +32% | 43% | 18.1× | 7.8% | +22.3% |
| Takeda Pharmaceutical 4502.T | Japan | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% | +7.1% |
| Bayer BAYN.DE | Germany | $61.2B | +46% | -2% | 14% | 12.3× | 2.1% | +1.9% |
| Galderma GALD.SW | Switzerland | $54.8B | +17% | +16% | 19% | 48.1× | 18.4% | +6.4% |
| AbbVie ABBV | United States | $515B | +45% | +11% | 36% | 18.4× | -0.1% | +6.0% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% | +2.7% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $47.3B | +1% | +12% | 23% | 35.4× | 28.4% | +11.7% |
| BeOne Medicines 688235.SS | China | $45.8B | +19% | +28% | 15% | 74.5× | 23.3% | +79.3% |
Pfizer has 38 bonds outstanding with $58.0B face value. The agencies rate it A; its bonds trade like A+. Weighted yield 5.43%, a spread of 66 bp over government bonds.